Julian Baker
Sits on 16 boards. Overboarded · 16 public boards Last updated September 27, 2026
Time on boards
- Boards served
- 16
- Current seats
- 16
- Board service
- 45 years
- Director since
- 2023
45 years of board service in total across 16 boards, counting each seat separately. Longest: Incyte Corp., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Madrigal Pharmaceuticals Inc. June 16, 202688.6%
-
Madrigal Pharmaceuticals Inc. June 20, 202590.5%
-
Incyte Corp. June 10, 202585.9%
-
Incyte Corp. June 12, 202489.6%
-
ACADIA Pharmaceuticals Inc. May 29, 202489.2%
-
Incyte Corp. June 14, 202392.3%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 29, 2026 | Kiniksa Pharmaceuticals International plc | Grant or award | +6,078 | — | — |
| May 29, 2026 | Kiniksa Pharmaceuticals International plc | Grant or award | +6,078 | — | — |
| Oct 1, 2025 | KALA BIO Inc. | Open-market sale | −50,640 | $1.38 | $69,883 |
| Oct 1, 2025 | KALA BIO Inc. | Open-market sale | −462,967 | $1.38 | $638,894 |
| Sep 30, 2025 | KALA BIO Inc. | Open-market sale | −21,376 | $1.60 | $34,202 |
| Sep 30, 2025 | KALA BIO Inc. | Open-market sale | −195,425 | $1.60 | $312,680 |
| Sep 3, 2025 | vTv Therapeutics Inc. | Grant or award | +4,308 | — | — |
| Sep 3, 2025 | vTv Therapeutics Inc. | Grant or award | +46,692 | — | — |
| Jun 3, 2025 | Kiniksa Pharmaceuticals International plc | Grant or award | +8,397 | — | — |
| Jun 3, 2025 | Kiniksa Pharmaceuticals International plc | Grant or award | +8,397 | — | — |
| Jun 5, 2024 | Kiniksa Pharmaceuticals International plc | Grant or award | +6,346 | — | — |
| Jun 5, 2024 | Kiniksa Pharmaceuticals International plc | Grant or award | +6,346 | — | — |
| Nov 21, 2023 | Madrigal Pharmaceuticals Inc. | Open-market purchase | +12 | $185.94 | $2,231 |
| Nov 21, 2023 | Madrigal Pharmaceuticals Inc. | Open-market purchase | +146 | $185.94 | $27,147 |
| Nov 21, 2023 | Madrigal Pharmaceuticals Inc. | Open-market purchase | +31 | $183.16 | $5,678 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.